These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24323134)

  • 21. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Ann Intern Med; 2018 Mar; 168(6):422-430. PubMed ID: 29459980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines.
    Shimizu R; Torii H; Yasuda D; Hiraoka Y; Kitada N; Hashida T; Yoshimoto A; Kita T; Kume N
    J Atheroscler Thromb; 2015; 22(9):949-57. PubMed ID: 25843151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC).
    Katz PM; Mendelsohn AA; Goodman SG; Langer A; Teoh H; Leiter LA
    Can J Cardiol; 2011; 27(2):138-45. PubMed ID: 21459260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
    Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
    Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins in chronic kidney disease: cardiovascular risk and kidney function.
    Deedwania PC
    Postgrad Med; 2014 Jan; 126(1):29-36. PubMed ID: 24393749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline.
    Awan AAY; Berenguer MC; Bruchfeld A; Fabrizi F; Goldberg DS; Jia J; Kamar N; Mohamed R; Pessôa MG; Pol S; Sise ME; Balk EM; Gordon CE; Adam G; Cheung M; Earley A; Martin P; Jadoul M
    Ann Intern Med; 2023 Dec; 176(12):1648-1655. PubMed ID: 38079642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of low-density lipoprotein targets.
    Whayne TF
    Angiology; 2013 Aug; 64(6):411-6. PubMed ID: 22734087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Lipid therapy in daily routine].
    Sonntag F; Schaefer JR; Gitt AK; Weizel A; Jannowitz C; Karmann B; Pittrow D; Bestehorn K
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2047-52. PubMed ID: 23023622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients?
    Jiménez Alvaro S; Marcén R; Teruel JL; Fernández Rodríguez A; Pascual J; Galeano C; Villacorta J; Burgos FJ; Ortuño J
    Transplant Proc; 2009; 41(6):2409-11. PubMed ID: 19715935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid lowering in liver and chronic kidney disease.
    Herrick C; Litvin M; Goldberg AC
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
    Ballantyne CM
    Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?
    Calice-Silva V; Muenz D; Wong MMY; McCullough K; Charytan D; Reichel H; Robinson B; Stengel B; Massy ZA; Pecoits-Filho R;
    Lipids Health Dis; 2023 May; 22(1):67. PubMed ID: 37231413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-sectional survey of the prevalence of reduced estimated glomerular filtration rate, albuminuria and cardiovascular risk in a native Spanish population.
    Robles NR; Felix FJ; Fernandez-Berges D; Perez-Castán JF; Zaro MJ; Lozano L; Alvarez-Palacios P; Garcia-Trigo A; Tejero V; Morcillo Y; Hidalgo AB
    J Nephrol; 2013; 26(4):675-82. PubMed ID: 23100180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.